Genmab — AGM Information 2013

Apr 17, 2013

News Details

Ad-hoc | 17 April 2013 16:00

Passing of Genmab A/S’ Annual General Meeting

Genmab A/S

17.04.2013 16:00

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Company Announcement

-- At Genmab A/S' Annual General Meeting held today on April 17, 2013 the
Annual Report for 2012 was approved
-- Discharge was given to the Board of Directors and the Executive Management
and the year's loss was carried forward
-- A new member was elected to the Board of Directors and two members of the
Board of Directors were re-elected
-- PricewaterhouseCoopers was re-elected as auditor of the Company
-- The proposal from the Board of Directors on the Board of Directors'
remuneration for 2013 and the proposals to amend Article 4A, Article 5,
Article 5A and Article 16 in the Articles of Association were adopted

Copenhagen, Denmark; April 17, 2013 - Genmab A/S (OMX: GEN) held its Annual
General Meeting, today April 17, 2013 at 2:00 PM at Tivoli Hotel & Congress
Center, Arni Magnussons Gade 2-4, DK-1577 Copenhagen V, Denmark.

At the meeting Chairman of the Board of Directors Dr. Anders Gersel Pedersen
gave - on behalf of the Board of Directors - a report on the Company's
activities during the past year. Chief Executive Officer Jan van de Winkel
presented plans for the year ahead, and Chief Financial Officer David Eatwell
presented the Annual Report for 2012 endorsed by the auditors. The report was
approved and discharge was given to the Board of Directors and the Executive
Management.

It was decided that the year's loss of DKK 456 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.

Mats Pettersson was elected to the Board of Directors for a one year period.
Dr. Anders Gersel Pedersen and Dr. Burton G. Malkiel were both re-elected to
the Board of Directors for a one year period.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected
as the Company's auditor.

The General Meeting adopted the proposals from the Board of Directors, as
follows:

-- The proposal to adopt the Board of Directors' remuneration for 2013.
-- The proposal to revise the provision to issue new shares in Article 4A in
the Articles of Association so that the authorization is increased from
nominally DKK 9,600,000 to nominally DKK 15,000,000 shares, so that the
authorization is split in two - with and without preemption right for the
existing shareholders - and so that the authorization is granted for a new
five year period.
-- The proposal to amend Article 5 to authorize the Board of Directors to
issue additional warrants - without pre-emption rights for the existing
shareholders - that give the right to subscribe up to nominally DKK 600,000
shares in the Company to members of the Company's Board of Directors, the
Company's employees and consultants as well as employees and consultants of
the Company's subsidiaries and to implement the corresponding capital
increases.
-- The proposal to revise the provision to raise loans against convertible
bonds or other convertible financial instruments in Article 5A so that the
authorization is split in two - with and without preemption right for the
existing shareholders - and so that the authorization is granted for a new
five year period. The limit in the authorization is furthermore raised to a
maximum of DKK 1.5 billion.
-- The proposal to amend Article 16 so that registered shareholders going
forward on their own initiative must submit an electronic address to the
Company to which notices can be sent.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); the DuoBody(tm) logo; HuMax(r); HuMax-CD20(r); DuoBody(r),
HexaBodyTM and UniBody(r). Arzerra(r) is a trademark of GlaxoSmithKline.

Company Announcement no. 14
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=428080

News Source: NASDAQ OMX

17.04.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Dänemark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---